Loading...
NPI 1497360648 · Las Vegas, NV · Physiological Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Advanced Molecular Pet Imaging LLC is a physiological laboratory provider located in Las Vegas, Nevada. This profile covers 8 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Advanced Molecular Pet Imaging LLC |
| Address | 5785 S Fort Apache Rd |
| City | Las Vegas |
| State | NV |
| ZIP | 89148 |
| Taxonomy | Physiological Laboratory |
| NPI Enumerated | September 14, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $0 |
The provider’s service mix is tightly focused on cardiac PET imaging and associated pharmacologic stress testing and injections: its top Medicare codes are A9555 (Rubidium rb-82 per study dose), 78431 (PET myocardial imaging with CT transmission, rest and stress), and 78434 (PET myocardial blood flow study at rest and stress), indicating an operation that performs myocardial perfusion PET studies with radiotracer administration and stress protocols. Several supporting codes (J2785, J0153, 93015, 96374) reflect routine use of pharmacologic stress agents and physiologic monitoring during these studies.
Revenue is highly concentrated: the precomputed top 3 Medicare codes account for 93.6% of this provider’s total Medicare revenue, with 78431 representing 56.4% and A9555 representing 33.8% of Medicare receipts and 78434 contributing 3.4%. This concentration means the provider’s Medicare financial profile is driven almost entirely by a narrow set of cardiac PET procedures and the rubidium radiotracer.
This entity is effectively a single-payer operation in scope: lifetime Medicare revenue is $1.4M while reported Medicaid revenue is $0, so all documented public-payer activity is through Medicare. Analysts should treat Medicaid exposure as negligible when modeling payer mix or population access for this provider.
Competitive standing on key codes is nationally prominent for radiotracer supply and high for PET procedures: A9555 ranks #16 of 1266 providers nationally (99th percentile; notably above typical national volume), and 78431 ranks #16 of 1377 providers nationally (99th percentile; labeled 'typical, unremarkable volume'). These rankings indicate the provider is among the top national reporters for rubidium tracer use and is a very high-volume reporter for myocardial PET imaging relative to peers.
Several codes are flagged as statistical outliers for volume relative to peers, signaling unusual procedural or supply reporting patterns: 93015 and 96374 both rank in the 99th percentile and are described as 'extreme outlier, far above typical national volume,' J7050 ranks #7 of 1837 (100th percentile; extreme outlier), and J0153 is reported with 14.6K claims and $0 revenue while ranking #5 of 361 (99th percentile; extreme outlier). These patterns suggest extensive, high-frequency use of monitoring, infusion, and certain injection codes in the practice’s workflow.
There are notable payment-reporting anomalies tied to high-volume codes: J0153 shows 14.6K claims with $0 avg paid/claim and $0 revenue despite a top-25 rank, and J7050 shows 4.6K claims with $1 avg paid/claim totaling $4.6K. These entries should prompt reviewers to examine claim adjudication patterns, modifier use, or supply-billing practices rather than assume typical per-unit reimbursement.
Operational tenure is relatively recent: the NPI was enumerated on 2020-09-14 (~6 years ago). Despite a comparatively short time since enumeration, the provider has established concentrated, high-volume activity in specialized cardiac PET services at the national level for several codes.
From a contracting and network-risk perspective, the provider’s heavy reliance on a narrow set of cardiac PET and radiotracer codes means payer exposure is concentrated; any changes in reimbursement or supply availability for A9555 or 78431 would disproportionately impact this provider’s Medicare revenue. Analysts evaluating network inclusion or rate negotiations should weigh the provider’s specialized capacity and its top-ranked position on rubidium tracer utilization.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78431 | The provider performs a PET myocardial imaging scan, a type of nuclear imaging test, with CT transmission scan that reveals blood flow to and from the heart (perfusion). Ejection fraction and… | 570 | $1,380 | $783.8K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 1,150 | $410 | $469.2K |
| 78434 | The provider performs a positron emission tomography (PET) study at both rest and stress to measure myocardial blood flow. Stress is induced by injection of a drug. Report this code in conjunction… | 570 | $80 | $47.3K |
| J2785 | Injection, regadenoson, 0.1 mg | 1,050 | $30 | $35.6K |
| 93015 | The provider supervises the recording of the electrical activity of the heart to examine any abnormality in its functioning by obtaining blood pressure and electrocardiograph readings at regular… | 570 | $60 | $31.9K |
| 96374 | The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition. | 570 | $30 | $17.1K |
| J7050 | Infusion, normal saline solution, 250 cc | 4,610 | $1 | $4.6K |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 14,650 | $0 | $0 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 8 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78431 | The provider performs a PET myocardial imaging scan, a type of nuclear imaging test, with CT transmission scan that reveals blood flow to and from the heart (perfusion). Ejection fraction and… | 60 | $0 | $0 |
| 78434 | The provider performs a positron emission tomography (PET) study at both rest and stress to measure myocardial blood flow. Stress is induced by injection of a drug. Report this code in conjunction… | 60 | $0 | $0 |
| 93015 | The provider supervises the recording of the electrical activity of the heart to examine any abnormality in its functioning by obtaining blood pressure and electrocardiograph readings at regular… | 80 | $0 | $0 |
| 96374 | The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition. | 80 | $0 | $0 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 80 | $0 | $0 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 30 | $0 | $0 |
| J2785 | Injection, regadenoson, 0.1 mg | 50 | $0 | $0 |
| J7050 | Infusion, normal saline solution, 250 cc | 80 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96374 | The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition. | 66 | 80 | 2,150 | $20 | $183.5K |
| J2785 | Injection, regadenoson, 0.1 mg | 20 | 30 | 470 | $80 | $50.7K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 6 | 10 | 90 | $130 | $34.3K |
| 93015 | The provider supervises the recording of the electrical activity of the heart to examine any abnormality in its functioning by obtaining blood pressure and electrocardiograph readings at regular… | 14 | 30 | 60 | $30 | $19.6K |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 4 | 10 | 160 | $40 | $10.2K |
| J7050 | Infusion, normal saline solution, 250 cc | 25 | 30 | 500 | $1 | $3.8K |
| 78431 | The provider performs a PET myocardial imaging scan, a type of nuclear imaging test, with CT transmission scan that reveals blood flow to and from the heart (perfusion). Ejection fraction and… | 4 | 10 | 60 | $20 | $1.7K |
| 78434 | The provider performs a positron emission tomography (PET) study at both rest and stress to measure myocardial blood flow. Stress is induced by injection of a drug. Report this code in conjunction… | 3 | 10 | 80 | $1 | $100 |
Other providers in the same ZIP code as Advanced Molecular Pet Imaging LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.